Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator

Circulation

Volumn 110, Issue 24, 2004, Pages 3646-3654

  Dorian, Paul ^a   Borggrefe, Martin ^b   Al Khalidi, Hussein R ^c   Hohnloser, Stefan H ^d   Brum, Jose M ^c   Tatla, Daljit S ^c   Brachmann, Johannes ^e   Myerburg, Robert J ^f   Cannom, David S ^g   Van Der Laan, Michael ^h   Holroyde, Michael J ^c   Singer, Igor ⁱ   Pratt, Craig M ^j  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e KLINIKUM COBURG   (Germany)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g Los Angeles Cardiology Associates   (United States)

^h PROCTER AND GAMBLE COMPANY   (United States)

ⁱ Methodist Medical Center   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Antiarrhythmia agents; Cardioversion; Defibrillation; Drugs; Tachycardia

Indexed keywords

AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; DEFIBRILLATORS, IMPLANTABLE; DOUBLE-BLIND METHOD; ELECTRIC COUNTERSHOCK; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMIDAZOLIDINES; MALE; MIDDLE AGED; PIPERAZINES; RECURRENCE; TACHYCARDIA, VENTRICULAR;

EID: 20844455272     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000149240.98971.A8     Document Type: Article

References (30)

1. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials: AVID, CASH and CIDS studies: Antiarrhythmics vs Implantable Defibrillator study, Cardiac Arrest Study Hamburg, Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-2078.
2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
3. Lee KL, Hafley G, Fisher JD, Gold MR, Prystowsky EN, Talajic M, Josephson ME, Packer DL, Buxton AE, for the Multicenter Unsustained Tachycardia Trial Investigators. Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial. Circulation. 2002;106:233-238.
4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Troutman CL, Anderson J, Johnson GW, McNulty SE, Davidson-Ray L, Clapp-Channing N, Luceri RM, Ip JH, and the SCD-HeFT Investigators. SCD-HeFT: the Sudden Cardiac Death in Heart Failure Trial, presented as a late-breaking clinical trial at the American College of Cardiology Scientific Sessions 2004. Available at: http://www.sicr.org/scdheft_results_acc_lbcc.pdf. Accessed September 16, 2004.
5. Irvine J, Dorian P, Baker B, O'Brien B, Roberts R, Gent M, Newman D, Connolly S, for the CIDS Investigators. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J. 2002;144:282-289.
6. Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, Prystowsky EN. Prevention of implantable-defibrillator shocks by treatment with sotalol: d,1-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. 1999;340:1855-1862.
7. Steinberg JS, Martins J, Sadanandan S, Goldner B, Menchavez E, Domanski M, Russo A, Tullo N, Hallstrom A, AVID Investigators. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J. 2001;142:520-529.
8. DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med. 2003; 49:1836-1847.
9. Greene M, Newman D, Geist M, Paquette M, Heng D, Dorian P. Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular tachyarrhythmias. Europace. 2000;2:263-269.
10. Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverter- defibrillators: incidence, management and prognostic implications. J Am Coll Cardiol. 1998;32:1909-1915.
11. Exner DV, Pinski SL, Wyse DG, Renfroe EG, Follmann D, Gold M, Beckman KJ, Coromilas J, Lancaster S, Hallstrom AP, for the AVID Investigators (Antiarrhythmics Versus Implantable Defibrillators). Electrical storm presages nonsudden death: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Circulation. 2001;103:2066-2071.
12. Echt DS, Liebsen PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Hunter ML, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
13. Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2004;110:112-116.
14. Singer I, Al-Khalidi H, Niazi I, Tchou P, Simmons T, Henthorn R, Holroyde M, Brum J. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol. 2004;43:39-43.
15. Signorini D. Sample size for Poisson regression. Biometrika. 1991;78:446-450.
16. Schouton HJ. Adaptive biased urn randomization in small strata when blinding is impossible. Biometrics. 1995;51:1529-1535.
17. Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. J Royal Stat Soc Series B. 2000;62:711-730.
18. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100-1120.
19. Rose MS, Gillis AM, Sheldon RS. Evaluation of the bias in using time to the first event when the inter-event intervals have a Weibull distribution. Stat Med. 1999;18:139-154.
20. Stephens MA. Use of Kolmogorov-Smirnov, Cramer-von Mises and related statistics without extensive tables. J R Stat Soc Series B. 1970;32:115-122.
21. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet. 1982;1:1142-1147.
22. Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, Karam R, Sonnenblick EH, Brum JMG, for the AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation. 2004;109:990-996.
23. Greene HL, for the CASCADE Investigators. The CASCADE study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol. 1993;72:70F-74F.
24. Dorian P. Amiodarone and defibrillation thresholds: a clinical conundrum. J Cardiovasc Electrophysiol. 2000;11:741-743.
25. Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol. 1993;72:72A-79A.
26. ks in guinea pig cardiac myocytes. Biochem Biophys Res Commun. 1994;202:265-270.
27. Qi XQ, Newman D, Dorian P. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. J Interv Card Electrophysiol. 1999;3:61-67.
28. Sheldon R, Rose S, Flanagan P, Koshman ML, Killiams S. Risk factor for syncope recurrence after a positive tilt-table test in patients with syncope. Circulation. 1996;93:973-981.
29. Villacastin J, Almendral J, Arenal A, Albertos J, Ormaetxe J, Peinado R, Bueno H, Merino JL, Pastor A, Medina O, Tercedor L, Jimenez F, Delcan JL. Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverter-defibrillators. Circulation. 1996;93:753-762.
30. Lee DS, Green LD, Liu PP, Dorian P, Newman DM, Curry Grant F, Tu JV, Alter DA. Effectiveness of implantabte defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol. 2003;41:1573-1582.